Basic Drug Information
\nGeneric Name\u200c: taletrectinib adipate
\nBrand Name\u200c: IBTROZI
\nDosage Form & Strength\u200c: immediate-release hard capsule; 200 mg (counted as taletrectinib free base)
\nInitial U.S. Approval\u200c: 2025
\nPackager\u200c: Nuvation Bio Inc.
\nIndications and Usage<\/p>\n
IBTROZI is a kinase inhibitor indicated for the treatment of adult patients with \u200clocally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)\u200c.<\/p>\n
Dosage and Administration
\nPatient Selection\u200c: Confirm the presence of ROS1 rearrangement(s) in tumor specimen prior to initiation of treatment.
\nRecommended Dosage\u200c: 600 mg orally once daily on an empty stomach (no food intake at least 2 hours before and 2 hours after taking IBTROZI).
\nContinue treatment until disease progression or unacceptable toxicity.
\nDosage Forms and Strengths<\/p>\n
Capsules: 200 mg of taletrectinib (free base), equivalent to 272 mg of taletrectinib adipate.<\/p>\n
Contraindications<\/p>\n
None<\/p>\n
Warnings and Precautions
\nHepatotoxicity\u200c: Monitor liver function tests prior to initiating treatment, every 2 weeks during the first 2 months of treatment, then monthly thereafter as clinically indicated. More frequent testing is required for patients who develop transaminase elevations. Withhold, resume at reduced dose, or permanently discontinue based on severity.
\nInterstitial Lung Disease (ILD)\/Pneumonitis\u200c: Monitor patients for new or worsening pulmonary symptoms indicative of ILD\/pneumonitis. Immediately withhold in patients with suspected ILD\/pneumonitis. Resume at the same or reduced dose, or permanently discontinue based on severity and resolution.
\nQTc Interval Prolongation\u200c: Monitor ECG and electrolytes prior to initiating and periodically during treatment. Withhold, then resume at same or reduced dose, or permanently discontinue based on severity.<\/p>\n","protected":false},"excerpt":{"rendered":"
Generic Name\u200c: taletrectinib adipate
\nBrand Name\u200c: IBTROZI
\nDosage Form & Strength\u200c: immediate-release hard capsule; 200 mg (counted as taletrectinib free base)
\nInitial U.S. Approval\u200c: 2025
\nPackager\u200c: Nuvation Bio Inc.<\/p>\n","protected":false},"featured_media":2348,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[99],"product_cat":[26],"product_tag":[],"class_list":["post-2347","product","type-product","status-publish","has-post-thumbnail","product_brand-innovent","product_cat-capsules","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n